The effect of treatment on health-related quality of life (HRQoL) is an important consideration for patients. In the LUX-Lung 8 trial, second-line afatinib improved survival outcomes versus erlotinib in patients with squamous cell carcinoma of the lung. In this report, afatinib was also associated with improvements in diseaserelated symptoms and HRQoL versus erlotinib, contributing to the overall clinical benefit of afatinib. Introduction: In the phase III LUX-Lung 8 trial, afatinib significantly improved progression-free survival (PFS) and overall survival (OS) versus erlotinib in patients with squamous cell carcinoma (SCC) of the lung progressing during or after platinum-based chemotherapy. Patient-reported outcomes (PROs) and health-related quality of life (QoL) in these patients are presented. Patients and Methods: Patients (n ¼ 795) were randomized 1:1 to oral afatinib (40 mg/d) or erlotinib (150 mg/d). PROs were collected (baseline, every 28 days until progression, 28 days after discontinuation) using the European Organization for Research and Treatment of Cancer QoL questionnaire and lung cancer-specific module. The percentage of patients improved during therapy, time to deterioration (TTD), and changes over time were analyzed for prespecified lung cancer-related symptoms and global health status (GHS)/QoL. Results: Questionnaire compliance was 77.3% to 99.0% and 68.7% to 99.0% with afatinib and erlotinib, respectively. Significantly more patients who received afatinib versus erlotinib experienced improved scores for GHS/QoL (36% vs. 28%; P ¼ .041) and cough (43% vs. 35%; P ¼ .029). Afatinib significantly delayed TTD in dyspnea (P ¼ .008) versus erlotinib, but not cough (P ¼ .256) or pain (P ¼ .869). Changes in mean scores favored afatinib for cough (P ¼ .0022), dyspnea (P ¼ .0007), pain (P ¼ .0224), GHS/QoL (P ¼ .0320), and all functional scales. Differences in adverse events between afatinib and erlotinib, specifically diarrhea, did not affect GHS/QoL. Conclusion: In patients with SCC of the lung, second-line afatinib was associated with improved prespecified disease-related symptoms and GHS/QoL versus erlotinib, complementing PFS and OS benefits with afatinib.
Introduction
Until recently, approved treatment options for patients with squamous cell carcinoma (SCC) of the lung have represented a significant unmet medical need, with only the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib, and docetaxel, approved in the second-line setting. 1 In the past few years, several new therapies have been approved in this setting, including immune checkpoint inhibitors (ie, programmed death 1 inhibitors [nivolumab, pembrolizumab] and programmed death ligand 1 [PD-L1] inhibitor [atezolizumab] ), antivascular endothelial growth factor receptor-2 antibody therapy (ramucirumab, combined with docetaxel), and the ErbB family blocker afatinib. [2] [3] [4] This rapid expansion of treatment options raises a question among clinicians of which new therapy would provide optimal clinical benefit for patients with relapsed/refractory disease after progression during or after chemotherapy. Afatinib is an irreversible ErbB family blocker. 5 In the phase III LUX-Lung 8 trial, which compared afatinib with erlotinib in patients with SCC of the lung after treatment failure during or after platinum-based chemotherapy, 6 afatinib improved progression-free survival (PFS; median 2.6 vs. 1.9 months; hazard ratio [HR] , 0.81; P ¼ .0103), overall survival (OS; median 7.9 vs. 6.8 months; HR, 0.81; P ¼ .0077), and disease control rate (DCR; 50.5% vs. 39.5%; P ¼ .0020) versus erlotinib. The adverse event (AE) profile in both treatment arms was consistent with previous experience. Treatment-related Grade 3 diarrhea was more frequent with afatinib (9.9%) than erlotinib (2.3%) and treatment-related Grade 3 rash/ acne was more frequent with erlotinib (10.4%) than afatinib (5.9%); otherwise, AE profiles were comparable. The rate of dose reduction because of AEs was higher for afatinib compared with erlotinib (26.5% vs. 14.2%); however, discontinuation rates because of AEs were similar between the 2 treatment arms (20.2% and 17.0% with afatinib and erlotinib, respectively). 6 On the basis of the results of LUX-Lung 8, afatinib was approved by the US Food and Drug Administration for the treatment of patients with metastatic squamous nonesmall-cell lung cancer (NSCLC) progressing after platinum-based chemotherapy, and by the European Medicines Agency for the treatment of locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. 7, 8 With the emergence of several new treatment options for SCC of the lung, 9 ,10 a key consideration when choosing the most appropriate treatment option is the effect on patients' health-related quality of life (HRQoL). In patients with NSCLC, disease-related symptoms, including cough, dyspnea, and pain, are known to have a profound effect on HRQoL and interfere with daily life activities. 11 Up to 68% of patients, when questioned, said they would prefer a therapy that improved disease-related symptoms without prolonging life, as opposed to a therapy that improved survival without symptom benefit. 12 On the basis of the importance of HRQoL, all phase III trials of afatinib in NSCLC have included fully integrated, comprehensive patient-reported outcome (PRO) evaluation. [13] [14] [15] In the LUX-Lung 3 and LUX-Lung 6 studies, first-line afatinib significantly improved global health status/quality of life (GHS/ QoL) and prespecified lung cancer-related symptoms (cough, dyspnea, and pain) versus platinum-based chemotherapy in patients with NSCLC and activating EGFR mutations. 13, 15 Symptom and QoL benefit with afatinib has also been shown in patients with relapsed/refractory NSCLC 16 and SCC of the head and neck. 17 Furthermore, several studies have shown that tumor progression in afatinib-treated NSCLC patients is associated with deterioration in HRQoL, indicating that PROs are a patient-relevant end point. 13, 18 In this article we report on the effect of afatinib on prespecified PROs and disease-related symptoms compared with erlotinib in LUX-Lung 8. In addition, because class-related gastrointestinal AEs associated with TKI therapy are known to have a negative effect on patients' QoL, and that diarrhea is frequently observed in afatinibtreated patients, 19 we also report on results from an exploratory patient substudy of LUX-Lung 8 that assessed the occurrence and management of diarrhea in individual patients.
Patients and Methods

Study Design and Patients
Details of the LUX-Lung 8 (NCT01523587) study design and patient eligibility criteria have been published previously. 6 Briefly,
this was an open-label, phase III, global, randomized study. Eligible patients were aged 18 years or older with a diagnosis of advancedstage NSCLC of squamous histology, had received at least 4 cycles of platinum-based doublet chemotherapy as first-line treatment of stage IIIB/IV NSCLC, with subsequent disease progression, and had to be eligible for second-line treatment. Patients were randomized 1:1 to receive either afatinib 40 mg or erlotinib 150 mg orally once daily. The primary end point was PFS according to a central independent radiology review (Response Evaluation Criteria In Solid Tumors version 1.1). The key secondary end point was OS.
Other secondary end points were objective response rate, DCR, tumor shrinkage, and PROs. The study protocol-designed in accordance with the Declaration of Helsinki, the International Conference on Harmonization Guideline for Good Clinical Practice, and applicable region-specific regulatory requirements-was approved by independent ethics committees at each center. All patients provided written informed consent for trial participation.
Assessment of PROs
The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) is comprised of 30 questions and incorporates multi-item scales as well as single-item measures. 20 These include: 1 GHS/QoL scale; 5 functional scales; 3 symptoms scales; and 6 single items to assess dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties. Each of the multi-item scales includes a different set of items, and no item occurs in more than 1 scale. 21 The lung cancer-specific module, Quality of Life Questionnaire Lung Cancer-13 (QLQ-LC13), is comprised of 13 questions and incorporates 1 multi-item scale to assess dyspnea, as well as a series of single items to assess pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. 21, 22 Patient-reported outcomes were assessed at the first visit of each treatment course, at the end of treatment, and 28 days after treatment discontinuation. The respective questionnaires were completed by the patients at the site before they saw the investigator-before clinical assessment, before any treatment at the clinic, and before the patients were provided with any new information about their disease statusto avoid influencing the questionnaire responses. Information on the usage of cough, dyspnea, and pain medication was also collected.
An exploratory substudy was undertaken to assess the occurrence and management of diarrhea at centers that agreed to participate. Individual patients from these centers who volunteered to participate were included. Patients were asked to complete a detailed daily diary on the occurrence of diarrhea and interventions taken. The objective of the diarrhea substudy was to compare afatinib and erlotinib in terms of intensity and duration of diarrhea in the first 12 weeks of treatment. No formal hypothesis was tested; all analyses from the substudy are descriptive in nature.
Statistical Analyses
Patient-reported outcome responses were converted to a 0 to 100 scale and analyzed in line with EORTC scoring algorithms. 20 The
HRQoL analyses focused on prespecified symptoms relevant to lung cancer, specifically cough (question [Q]1 from QLQ-LC13), dyspnea (Q3-Q5 from QLQ-LC13), and pain (Q9 and Q19 from QLQ-C30). GHS/QoL (Q29 and Q30 from QLQ-C30) was also analyzed. For each of the summary scales and items that measured cough, dyspnea, and pain, the 2 treatment arms were compared in terms of 3 analyses. First, the proportion of patients who were improved, defined as an improvement of at least 10 points from baseline score at any time during the study, was compared. All randomized patients were included in the denominator. Second, the time to deterioration (TTD), defined as the time to a 10-point worsening from the baseline score, was evaluated. Patients who died before deterioration were analyzed as having deteriorated at the time of death. Patients with disease progression but without scale deterioration were censored at the time of the last scale measurement. Patients with no HRQoL assessments were censored at the day of randomization. Third, cough, dyspnea, and pain scores over time were assessed using a mixed-effects growth curve model with the average profile over time for each end point described by a piecewise linear model adjusted for the fixed effect race. In addition, all single items and subscales (functional and symptom) from the EORTC QLQ-C30 and QLQ-LC13 questionnaires were analyzed to summarize the effect of therapy on the time profile of the measures, and to examine the consistency of component items with the composite measures.
For functioning scales, a higher score represents a 'better' level of functioning, and deterioration in scales or items related to functioning was defined as a decrease of at least 10 points from baseline. Because some missing PRO data is inevitable, correlation analyses were conducted to determine whether missing data because of patient dropout was associated with patient characteristics or other factors. Robustness of the primary PRO results from the longitudinal model were assessed by varying data cutoff times and model truncation times, and sensitivity analyses were carried out using joint and pattern-mixture models.
Results
Patients
A total of 795 patients were randomized to receive afatinib (n ¼ 398) or erlotinib (n ¼ 397). Baseline characteristics were generally similar between the 2 arms and have been reported previously. 6 Briefly, the median age was 64 years, 666 (83.8%) patients were male, 172 (21.6%) were Eastern Asian, and 728 (91.6%) were ever smokers.
Baseline Scores and Compliance
Baseline PRO questionnaires were completed by 95.5% of afatinib-treated patients and 95.0% of erlotinib-treated patients. Baseline symptom scores for cough, dyspnea, and pain were low and balanced between treatment arms ( Table 1 ). The mean (SD) baseline score for GHS/QoL was 60.8 (21.0) for the afatinib arm and 60.2 (21.6) for the erlotinib arm; higher scores reflect better GHS/QoL. Questionnaire completion rates according to treatment cycle ranged from 77.3% to 99.0% in the afatinib arm and from 68.7% to 99.0% in the erlotinib arm ( Figure 1) . A similar proportion of patients in both arms completed at least 1 PRO 
Patient-Reported Outcomes With Afatinib Versus Erlotinib
questionnaire after baseline (87.7% of afatinib-treated patients and 89.2% of erlotinib-treated patients). Most patients for whom HRQoL was not measured after the start of treatment either died or had disease progression before the second scheduled post-baseline PRO assessment at day 56.
Patient-Reported Outcomes
Proportion of Patients With Improvements
The percentage of patients reporting improved scores for GHS/ QoL (35.7% vs. 28.3%; P ¼ .041) and cough (43.4% vs. 35.2%; P ¼ .029) was significantly higher with afatinib than erlotinib ( Figure 2 ). There was no significant difference in the proportion of patients with improved dyspnea (51.3% vs. 44.1%; P ¼ .061), or pain (40.2% vs. 39.2%; P ¼ .775) between treatment arms ( Figure 2 ). Improvements in individual dyspnea-and pain-related items, as well as in functional scales of QLQ-C30, are shown in Supplemental Table 1 in the online version. Afatinib was associated with a significant improvement in 'dyspnea walked' (34.6% vs. 26.5%; P ¼ .022) but did not significantly improve any other individual symptom items, or functional scales of QLQ-C30, versus erlotinib. 
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Time to Deterioration
Afatinib significantly delayed TTD of dyspnea versus erlotinib (median 2.6 vs. 1.9 months; P ¼ .008; Figure 3A) , with a consistent pattern of improvement across dyspnea subcategories ( Figure 4 ). There was no significant difference in TTD of cough (4.5 vs. 3.7 months; P ¼ .256; Figure 3B ) or pain (2.5 vs. 2.4 months; P ¼ .869; Figure 3C ) between treatment groups. TTD was also similar for GHS/ QoL and functional scales with afatinib versus erlotinib ( Figure 4 ).
Scores Over Time
Scores over time significantly favored afatinib over erlotinib for cough (mean difference ¼ À3.60; P ¼ .0022), dyspnea (mean difference ¼ À3.25; P ¼ .0007), and pain (mean difference ¼ À2.72; P ¼ .0224; Figure 5 ); significant improvements over time were also observed for all individual items with the exception of 'have pain,' 'pain in arm or shoulder,' and 'pain in other parts.' Significant differences in favor of afatinib were observed for GHS/QoL (mean difference ¼ 1.95; P ¼ .0320) and all functioning scales over time ( Figure 5 ).
Correlation analyses between missing data, and patient characteristics and treatment, showed a weak positive correlation over the first few weeks of treatment with a baseline Eastern Cooperative Oncology Group performance status of 1 (see Supplemental Table 2 in the online version), as well as a weak positive correlation with erlotinib treatment at weeks 12 and 36, indicating that more erlotinib-treated patients dropped out at these time points relative to afatinib-treated patients (see Supplemental Table 3 in the online version). In each treatment arm, weak positive correlations, particularly during the early weeks of the trial, were associated with severity of dyspnea and pain symptoms at baseline but not with severity of cough; worse GHS/QoL score at baseline was also associated with missing data because of patient dropout (see Supplemental Table 4 in the online version). When GHS/QoL and symptoms were examined with respect to the last known assessment for each measure, the correlations were stronger than those found versus the baseline assessment, suggesting that the patterns of missing data for the parameters described do depend on the observed data (data on file). 
Enriqueta Felip et al
Clinical Lung Cancer January 2018 -79 Differences in mean scores for cough, dyspnea, and GHS/QoL did not vary when different data cutoffs and truncation points were used (see Supplemental Figure 1 in the online version), suggesting the results of the primary PRO analysis were robust. Sensitivity analyses were conducted using 3 joint models on the basis of time to treatment termination (censored at time of database lock), and time to last assessment (either uncensored or censored at time of database lock) as the time to dropout event. The estimates of treatment effect consistently favored afatinib over erlotinib for each end point, supporting the primary PRO analysis conclusions (see Supplemental Table 5 in the online version). Further, results of sensitivity analyses on the basis of pattern-mixture models generally reflected the primary PRO analysis (see Supplemental Table 6 in the online version). Compared with the primary PRO analysis, a stronger between-treatment difference in favor of afatinib was observed for cough, suggesting that, at least for this measure, the results of the primary PRO analysis might be conservative.
Analyses of Individual PRO Items
Status changes (improved, stable, or worsened) in individual items of QLQ-C30 and QLQ-LC13 are shown in Supplemental Table 7 in the online version. Afatinib treatment was associated with a greater percentage of patients with improvements in overall health rate versus erlotinib (Q29 from QLQ-C30; 43.4% vs. 35.8%; P ¼ .045). There were also trends toward a greater percentage of patients with improvements in QoL rate (Q30 from QLQ-C30; 43.1% vs. 36.0%; P ¼ .060) and 'felt weak' (Q12 from QLQ-C30; 31.2% vs. 24.6%; P ¼ .058) with afatinib versus erlotinib. Compared with erlotinib, a greater percentage of patients receiving afatinib had worsening of diarrhea (Q17 from QLQ-C30; 77.2% vs. 54.0%; P ¼ .146) and sore mouth (Q6 from QLQ-LC13; 60.7% vs. 37.5%; P ¼ .113; see Supplemental Table 7 in the online version), but the differences were not statistically significant.
Differences in TTD and mean scores over time between treatment arms for individual items of the QLQ-C30 and QLQ-LC13 are shown in Supplemental Figures 2 and 3 , respectively, in the online version. Overall, most individual items tended to favor afatinib for TTD as well as changes over time. However, as expected because of the observed AE profiles of afatinib and erlotinib in LUX-Lung 8, the individual items of diarrhea and sore mouth favored erlotinib.
Patients' Perspectives on the Effect of Diarrhea
In LUX-Lung 8, the frequency of treatment-related Grade 3/4 diarrhea was higher with afatinib (9.9%/0.5%) than erlotinib (2.3%/0.3%), although discontinuations because of diarrhea were low for both treatment arms (4.1% with afatinib and 1.5% with erlotinib). 6 In a small substudy to assess the effect of diarrhea from a patient's perspective, a selected subset of 63 patients (afatinib 
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Medication Usage
A smaller proportion of patients in the afatinib group took pain medication (afatinib 52%; erlotinib 59%; odds ratio, 0.75; 95% confidence interval, 0.57-1.00; P ¼ .0508), but the difference was not statistically significant. No differences were observed between treatment groups in the proportion of patients who took medication for cough or dyspnea.
Discussion
The recent phase III LUX-Lung 8 study showed significantly prolonged PFS and OS with afatinib versus erlotinib in patients with SCC of the lung after failure during or after platinum-based chemotherapy. 6 As with many oncology trials, PFS was chosen as the primary end point for LUX-Lung 8 because, unlike OS, it is not influenced by differences in subsequent therapies. 23 However, it is important to assess PROs/HRQoL alongside survival outcomes to validate the clinical meaningfulness of observed improvements in PFS and to ensure any extended lifespan attained during treatment is as comfortable as possible for patients. 24 Hence, comprehensive PRO/HRQoL assessments were prespecified in the LUX-Lung 8 trial to provide an essential component to analysis of the benefit/risk profile of treatment in conjunction with efficacy and safety assessments. 25 We prespecified 3 key NSCLC-related symptoms that are reported to matter most to patients: dyspnea, cough, and pain. 26 These symptoms can have a profound effect on HRQoL and interfere with daily life activities in patients with NSCLC, although symptom burden at baseline was low and balanced between treatment arms in LUX-Lung 8. Three approaches for the analysis of the prespecified symptoms were stipulated in the protocol: proportion of patients with clinically meaningful improvements in each symptom, analysis of TTD of symptoms, and longitudinal analysis of symptoms over time. These approaches, also used in previous afatinib trials, 13, 15 broadened the perspective of the results and enhanced their interpretation. Compared with erlotinib, afatinib treatment was associated with a significantly higher number of patients reporting improved GHS/QoL and cough, a significant delay in TTD of dyspnea, and significantly improved mean scores over time for cough, dyspnea, and pain. These data complement the consistent benefit observed with afatinib across all efficacy end points, including OS, PFS, and DCR, in patients with SCC of the lung who have disease progression during or after platinum-based chemotherapy. Overall, these findings are consistent with recent results in the second-line setting of recurrent and/or metastatic SCC of the head and neck, wherein the PFS benefit observed with afatinib over methotrexate was also associated with a significant improvement in PROs. 17 The primary analysis of LUX-Lung 8 demonstrated that the overall tolerability profile was similar between treatment arms; 57.1% and 57.5% of patients experienced Grade ! 3 AEs with afatinib and erlotinib, respectively. Permanent treatment discontinuations were also comparable (occurring in 20.2% of afatinibtreated patients and 17.0% of erlotinib-treated patients), although dose reductions occurred more frequently with afatinib (26.5%) than erlotinib (14.2%). 6 Furthermore, AEs were consistent with the mechanism of action of afatinib, including characteristic classrelated gastrointestinal (diarrhea, stomatitis) and cutaneous (rash/ acne) events. As with all TKIs that target EGFR, afatinib is associated with diarrhea; the incidence of treatment-related Grade 3/4 diarrhea in LUX-Lung 8 was 9.9%/0.5% with afatinib, compared with 2.3%/0.3% in the erlotinib arm. 6 In the present study, the increased incidence of diarrhea with afatinib versus erlotinib was also reflected in patients' responses to the relevant individual items of QLQ-C30 and QLQ-LC13. A voluntary patient substudy, undertaken in < 10% of the overall trial population, allowed further patient-level detail to be gathered on the occurrence and management of diarrhea. Although the frequency and duration of all-Grade diarrhea was greater with afatinib than erlotinib, median duration of Grade ! 3 diarrhea was 3 days. Overall, cases of Grade ! 3 diarrhea were intermittent, being experienced on 1.5% of the total number of patient-days of treatment. Furthermore, no patients in the substudy (compared with 4.1% of patients in the overall population) discontinued treatment with afatinib because of diarrhea, possibly as a result of the recommended afatinib dose-reduction scheme that is specified in the prescribing information and designed to manage such AEs. 8 Of note, post hoc analyses of LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 have shown that dose adjustment of afatinib does not affect efficacy. [27] [28] [29] Overall, although diarrhea is a frequent AE with afatinib, episodes generally appear to be transient and manageable with antidiarrheal medication and dose modification. Consequently, incidence of diarrhea does not affect overall GHS/QoL, which is improved with afatinib versus erlotinib. Although several other phase III trials have evaluated the effect of reversible EGFR inhibitors (ie, erlotinib and gefitinib) on cancerrelated symptoms and HRQoL in NSCLC patients, there is an overall lack of consensus in the findings, which might be related to the different assessment tools used to capture PROs. In the phase III BR.21 trial, which also used the well validated QLQ-C30 and QLQ-LC13 questionnaires, second-or third-line erlotinib significantly improved symptoms and delayed TTD for cough, dyspnea, and pain versus placebo, reinforcing the appropriateness of these instruments for detecting improvements in PROs in a second-line treatment setting. 30 However, in the phase III Tarceva in Treatment of Advanced NSCLC (TITAN) study, there was no significant difference in the TTD of symptoms with second-line erlotinib versus docetaxel or pemetrexed, on the basis of the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire. 31 Likewise, there is a lack of consensus regarding the effect of gefitinib on HRQoL in randomized studies. Some phase III trials have shown that significantly more patients attain sustained and clinically relevant A number of steps were taken to ensure the validity and robustness of the PRO results, and data collection was optimized to ensure their clinical relevance. To avoid bias, patients answered questions before meeting physicians and completed the questionnaires themselves, with data collected at the first visit of each treatment cycle. In addition, because of the importance of minimizing the occurrence of missing data in PRO analyses, 15, 37 it is noteworthy that compliance with questionnaire completion ranged from 77% to 99% throughout the study for patients treated with afatinib. This high level of compliance was in line with that observed in LUX-Lung 3 (87%-99%) and LUX-Lung 6 (approximately 90%). 13, 15 The EORTC QLQ-C30 and QLQ-LC13 instruments used in this study are well validated, and allow the accurate assessment of PROs. 20, 22 However, PRO assessments are often discontinued at the time of disease progression, meaning that symptom deterioration beyond progression is not taken into account by the data, and PRO benefits might be overestimated. In LUX-Lung 8, this issue was avoided by scheduling a PRO assessment at the follow-up visit, 28 days after study drug discontinuation. Nevertheless, the collection of PRO data after disease progression also has an effect on data interpretation because of variations in postprogression treatments. In addition, patients might have been less inclined to complete questionnaires when feeling unwell, so the data might under-represent patients with more severe symptoms. Although differences in questionnaire compliance between treatment arms have the potential to introduce bias to the data, in the current study, sensitivity analyses conducted for individual disease-related symptoms (eg, cough, dyspnea) and GHS/ QoL using additional data cutoffs and truncation points confirmed the robustness of the primary PRO analysis results.
Conclusion
In summary, second-line afatinib significantly improved symptoms of cough and GHS/QoL and significantly delayed TTD of dyspnea compared with erlotinib in patients with SCC of the lung. Mean scores over time also significantly favored afatinib over erlotinib for cough, dyspnea, pain, GHS/QoL, and all functional scales. Differences in AEs between afatinib and erlotinib were reflected in the PRO outcomes, with a greater proportion of patients in the afatinib arm experiencing worsening diarrhea and sore mouth compared with erlotinib, although these differences did not appear to affect overall GHS/QoL. These data, combined with significant improvements in PFS and OS with afatinib, should be taken into account when considering treatment options for patients with SCC of the lung after failure during or after platinum-based chemotherapy.
Clinical Practice Points
Squamous cell carcinoma of the lung remains a disease with high unmet medical need, particularly for patients with relapsed/refractory disease after platinum-based chemotherapy. Among other emerging therapeutic options, afatinib was approved in this setting after showing significant improvements in PFS and OS versus erlotinib in the phase III LUX-Lung 8 trial. Because HRQoL is an important consideration for cancer patients, the effect of newer treatments, including afatinib, on PROs of disease-related symptoms and GHS might be a key factor in treatment choice. In LUX-Lung 8, second-line afatinib was associated with a significantly higher percentage of patients reporting improvements in cough and GHS/QoL, and significantly delayed TTD in dyspnea, versus erlotinib. Mean scores over time also significantly favored afatinib for cough, dyspnea, pain, GHS/QoL, and all functional scales. As expected, because of the observed AE profiles for each agent, PROs for worsening of diarrhea favored erlotinib over afatinib (nonsignificant difference). However, episodes of diarrhea were shown to be transient and manageable, and did not affect GHS/QoL. The improvements in disease-related symptoms and QoL observed with afatinib versus erlotinib in patients with SCC of the lung progressing on/after platinum-based chemotherapy contribute to the overall clinical benefit of afatinib. Combined with the significant improvements in PFS and OS observed with afatinib versus erlotinib in LUX-Lung 8, and a predictable and manageable safety profile, these findings suggest that afatinib is a favorable treatment option in this setting. 
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